Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Acquisition

10 Sep 2015 07:00

RNS Number : 6162Y
CATCo Reinsurance Opps Fund Ltd
10 September 2015
 

 

 

CATCo Reinsurance Opportunities Fund Ltd. ("the Company")

 

CATCo Investment Management Ltd. Sale of Assets

 

 

To: SFM, London Stock Exchange and Bermuda Stock Exchange

Date: 10 September 2015

 

The Company announces that its investment manager, CATCo Investment Management Ltd. ("CATCo IM") has agreed to sell substantially all its assets to Markel Corporation ("Markel"), a U.S. based diverse financial holding company whose principal business markets and underwrites specialty insurance products. Listed on the New York Stock Exchange, Markel has a market capitalisation of approximately $11.5 billion and generated operating revenues of over $5 billion for the year ended 31 December 2014.

 

Markel and CATCo IM have entered into an agreement whereby Markel will acquire substantially all of the assets of CATCo IM, subject to the satisfaction of certain conditions. Upon completion of the acquisition which is expected to occur in the fourth quarter of 2015, the business will operate as Markel CATCo Investment Management Ltd. ("Markel CATCo"). Also upon completion of the acqusition, Markel CATCo will manage the Company.

 

Prior to completion of the acquisition, the Company will continue to operate and interact with its investment manager as normal, and there will be no changes to management personnel.

 

Upon completion of the acquisition, the existing CATCo IM management team, led by Chief Executive Officer Tony Belisle, will transition into corresponding roles at Markel CATCo and will continue to operate the business from its Hamilton, Bermuda headquarters, under Markel's ownership. Responsibility for existing and potential reinsurance market client relationships will remain with the CATCo IM team that will transition to Markel CATCo with the reinsurance business conducted as before. The existing CATCo IM senior management team will remain with the business and are incentivised to stay with the business for a minimum of three to five years.

 

The Company believes this is a progressive transaction for all stakeholders in that the combined strengths of these companies will further support the development of innovative structures and new products for reinsurance market clients.

 

Nigel Barton, Chairman, CATCo Reinsurance Opportunities Fund Ltd. said:

 

"The Board sees this as a very positive development for investors and reinsurance market clients alike. In bringing together the strengths of CATCo IM and Markel, the Board expects this transaction to generate future benefits for the Company's investors."

 

Tony Belisle, Chief Executive Officer of CATCo Investment Management Ltd. said: 

 

"We are excited to join forces with Markel, a leading global specialty insurer and reinsurer which operates with a strong commitment to its core values and distinguished corporate culture. We felt this partnership offered a rare opportunity for CATCo IM to combine with a culturally similar organization which shares our results-oriented commitment to success and market leadership.

 

"We are confident that uniting the strength of the Markel brand and its global reach with CATCo IM's differentiated product innovation capabilities will serve to improve our value proposition for investors and cedants. CATCo has grown significantly since its launch in 2010 and the agreement with Markel will allow the same management team to maintain its commitment to both client service and continued product development."

 

 

For further information:

 

Judith Wynne,

Company Secretary and General Counsel

CATCo Investment Management Ltd.

Telephone: +44 7986 205364

Email: judith.wynne@catcoim.com

 

Mark Way

Investor Relations Director

CATCo Investment Management Ltd.

Telephone: +44 7786 116991

Email: mark.way@catcoim.com

 

David Benda / Hugh Jonathan

Numis Securities Limited

Telephone: +44 (0) 20 7260 1000

 

 

- ends -

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQURAARVVAKARR
Date   Source Headline
29th Mar 201111:40 amRNSIssue of Equity
29th Mar 201111:36 amRNSDirector/PDMR Shareholding
7th Mar 20111:49 pmRNSNet Asset Value(s)
7th Feb 20118:30 amRNSPortfolio Update
7th Feb 20118:11 amRNSNet Asset Value(s)
14th Jan 20117:00 amRNSPortfolio Update
7th Jan 20113:33 pmRNSHolding(s) in Company
23rd Dec 201011:00 amRNSHolding(s) in Company
20th Dec 20107:00 amRNSResult of Placing and Admission to SFM
13th Jul 20064:12 pmRNSHolding(s) in Company
10th Jul 20063:20 pmRNSHolding(s) in Company
7th Jul 20062:51 pmRNSOffer for Cambridge Antibody
3rd Jul 20064:56 pmRNSDirectorate Change
30th Jun 20064:12 pmRNSHolding(s) in Company
30th Jun 20064:06 pmRNSDelisting
30th Jun 200610:27 amRNSAdditional Listing
30th Jun 20067:02 amRNSOffer for Cambridge Antibody
27th Jun 20062:26 pmRNSHolding(s) in Company
27th Jun 200612:34 pmRNSHolding(s) in Company
23rd Jun 20062:25 pmRNSAppointment of Directors
22nd Jun 20063:07 pmRNSRule 8.3- CAT
22nd Jun 200611:31 amRNSCAT Limited appoints new CE
22nd Jun 200611:11 amRNSEPT Disclosure
22nd Jun 200611:09 amRNSEPT Disclosure
22nd Jun 20067:02 amRNSOffer for Cambridge Antibody
21st Jun 20065:11 pmRNSRule 8.1- C.A.T.
21st Jun 200611:30 amRNSEPT Disclosure
21st Jun 200610:20 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
19th Jun 20063:25 pmRNSRule 8.3 - Cambridge Antibody
19th Jun 20061:07 pmRNSRule 8.3- (CAT)
19th Jun 200611:30 amRNSEPT Disclosure
19th Jun 200611:23 amRNSEPT Disclosure
19th Jun 200610:33 amRNSEPT Disclosure
16th Jun 200611:45 amRNSEPT Disclosure
16th Jun 200611:24 amRNSEPT Disclosure
16th Jun 200611:08 amRNSEPT Disclosure
15th Jun 20065:01 pmRNSEPT Disclosure
15th Jun 20062:48 pmRNSRule 8.3- (CAT)
15th Jun 20062:17 pmRNSRule 2.10 Announcement
15th Jun 200612:45 pmRNSEPT Disclosure
15th Jun 200611:36 amRNSEPT Disclosure
14th Jun 20063:38 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20063:05 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20061:43 pmRNSRule 8.3- (CAT)
14th Jun 200611:36 amRNSEPT Disclosure
14th Jun 200611:15 amRNSEPT Disclosure
14th Jun 200610:59 amRNSEPT Disclosure
14th Jun 200610:23 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.